REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 81 filers reported holding REATA PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $11,676,459 | +133.7% | 114,520 | +108.4% | 0.10% | +108.3% |
| Q1 2023 | $4,997,235 | -49.9% | 54,963 | -79.1% | 0.05% | -42.2% |
| Q4 2022 | $9,976,326 | +35.2% | 262,604 | -10.5% | 0.08% | +33.9% |
| Q3 2022 | $7,377,000 | +386.3% | 293,500 | +533.9% | 0.06% | +342.9% |
| Q1 2022 | $1,517,000 | -43.8% | 46,300 | +167.6% | 0.01% | -61.1% |
| Q2 2020 | $2,700,000 | +157.1% | 17,300 | +137.8% | 0.04% | -45.5% |
| Q1 2020 | $1,050,000 | -70.8% | 7,275 | -58.6% | 0.07% | -25.0% |
| Q4 2019 | $3,593,000 | +833.2% | 17,576 | +266.2% | 0.09% | +700.0% |
| Q3 2019 | $385,000 | -51.4% | 4,800 | -42.9% | 0.01% | -60.7% |
| Q2 2019 | $792,000 | -20.1% | 8,400 | -76.0% | 0.03% | -65.4% |
| Q4 2017 | $991,000 | +27.4% | 35,000 | +40.0% | 0.08% | +14.1% |
| Q3 2017 | $778,000 | – | 25,000 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Conrad N. Hilton Foundation | 63,481 | $7,847,000 | 100.00% |
| CPMG Inc | 2,896,901 | $358,115,000 | 55.16% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 140,000 | $17,307,000 | 26.62% |
| Corriente Advisors, LLC | 525,000 | $64,901,000 | 15.45% |
| DUMAC, INC. | 76,050 | $9,401,000 | 7.33% |
| MADDEN SECURITIES Corp | 35,152 | $4,345,000 | 2.80% |
| Biondo Investment Advisors, LLC | 113,692 | $14,055,000 | 2.69% |
| Duquesne Family Office | 749,897 | $92,702,000 | 2.50% |
| LBJ Family Wealth Advisors, Ltd. | 30,368 | $3,754,000 | 2.44% |
| Integral Health Asset Management, LLC | 50,000 | $6,181,000 | 1.84% |